Skip to main content
Novel Self-Assembling Nanoparticles for Extended Duration Local Anesthetics

Novel Self-Assembling Nanoparticles for Extended Duration Local Anesthetics

Unmet Need An estimated 40 million surgeries are performed every year in the United States. Out of this population, an estimated 80% had post-operative pain with 75% reporting it as moderate to extreme. Local anesthetics…

Read More

Non-opioid treatment for chronic pain using a neurotensin receptor 1 modulator

Non-opioid treatment for chronic pain using a neurotensin receptor 1 modulator

Unmet Need For individuals experiencing chronic pain, day-to-day tasks and activities can become difficult or impossible. It can also lead to other long-term health challenges including insomnia, stress, anxiety, and depression. Chronic pain is so…

Read More

Clenbuterol Therapy for Amyotrophic Lateral Sclerosis

Clenbuterol Therapy for Amyotrophic Lateral Sclerosis

Unmet Need Amyotrophic lateral sclerosis (ALS) is a debilitating disease with progressive loss of muscle function and inevitable death usually in 3-5 years. There are currently two available therapies on the market which prolong life…

Read More

Method for treatment of dementia associated with Alzheimer’s disease and other neurodegenerative diseases

Method for treatment of dementia associated with Alzheimer’s disease and other neurodegenerative diseases

Unmet Need There are over 50 million people worldwide with dementia, with about 10 million new cases diagnosed every year. Though approximately 70% of dementia cases are associated with Alzheimer's disease patients, there is no…

Read More

A method of treating opioid dependence without opioid-based ingredients

A method of treating opioid dependence without opioid-based ingredients

Unmet Need In the United States, over 11% of adults experience daily pain and over 150 million prescriptions for opioids were dispensed in 2019. More than 11.5 million persons 12 years and older misuse prescription…

Read More

New selective small molecule inhibitors for the treatment of pain and itch

New selective small molecule inhibitors for the treatment of pain and itch

Unmet Need In the United States, an estimated 50 million adults suffer from chronic pain and around 20 million adults suffer from high-impact chronic pain. Ongoing difficulty in safely treating pain has led to the…

Read More

Novel drugs for the treatment of dystonia

Novel drugs for the treatment of dystonia

Value Proposition Dystonia is a classification of rare and debilitating movement disorders, for which there exists few therapeutic options. Treatments include therapy with botulinum neurotoxin to induce paralysis or deep brain stimulation. Not only are…

Read More

Beta-arrestin inhibition to prevent S1P1 internalization as a treatment for intracranial diseases

Beta-arrestin inhibition to prevent S1P1 internalization as a treatment for intracranial diseases

Value Proposition Glioblastomas (GBMs) are among the most common and deadly malignant brain tumors with a mean survival time of approximately 14-15 months following diagnosis. Current treatments for GBMs include surgery, radiation, and chemotherapy, however,…

Read More

Novel dystonia treatment drugs

Novel dystonia treatment drugs

Value Proposition Dystonia is a movement disorder characterized by sustained, often painful involuntary postures, causing motor disabilities and a marked decrease in quality of life. Dystonia is the third most common movement disorder behind Parkinson’s…

Read More

Have Questions?

Please contact us or subscribe for more opportunities

Stay in Touch with Us